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Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women Raymond C. Rosen, PhD, Nancy N. Maserejian, ScD, Megan K. Connor, MPH, Michael L. Krychman, MD, Candace S. Brown, PharmD, MSN, and Irwin Goldstein, MD In this registry study, most women with hypoactive sexual desire disorder were in long-term partner relationships with high levels of overall relationship satisfaction. Compared with premenopausal women, postmenopausal women were more likely to seek help for their disorder, despite the similarly high levels of distress associated with hypoactive sexual desire disorder.
406
Hot flashes and cardiac vagal control during women's daily lives Rebecca C. Thurston, PhD, Israel C. Christie, PhD, and Karen A. Matthews, PhD Among women with hot flashes, acute decreases in high-frequency heart rate variability were observed during physiologically monitored and self-reported hot flashes in the ambulatory setting. These findings indicate acute decreases in cardiac vagal control during hot flashes, supporting a role for the autonomic system in hot flashes.
413
Association of leisure physical activity and sleep with cardiovascular risk factors in postmenopausal women Rachel S. Casas, MD, Kelley K. Pettee Gabriel, PhD, Andrea M. Kriska, PhD, Lewis H. Kuller, MD, DrPH, and Molly B. Conroy, MD, MPH In this study cardiovascular risk factors were more favorable in highly active women relative to less active women regardless of sleep.
420
The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial Noha A. Mousa, MD, PhD, Riham Eiada, MD, Pavel Crystal, MD, Dan Nayot, MD, and Robert F. Casper, MD, FRCS(C) Postmenopausal women were enrolled in this study, and their breast background enhancement was analyzed objectively and subjectively before and after treatment.
426
Pomegranate seed oil in women with menopausal symptoms: a prospective randomized, placebo-controlled, double-blinded trial Leo Auerbach, MD, Julia Rakus, MD, Clemens Bauer, MD, Christopher Gerner, MD, PhD, Ronald Ullmann, MSc, Helge Wimmer, MSc, and Johannes Huber, MD, PhD Pomegranate seed oil does not significantly reduce hot flashes in postmenopausal women within a 12-week observation period. Twelve weeks after cessation of treatment, the frequency of hot flashes was significantly reduced compared with placebo, suggesting that further studies are needed to investigate the long-term effect. This cross-sectional study analyzed data from 3,965 postmenopausal women from Latin America and determined that a waist circumference cutoff value of 88 cm was optimal for defining the metabolic syndrome.
438
The Chinese Utian Quality of Life Scale for women around menopause: translation and psychometric testing Ping-Ling Chen, PhD, Hsiang-Tai Chao, MD, PhD, Kuei-Ru Chou, RN, PhD, Hui-Mei Huang, RN, MSN, Sue-Yueh Cheng, RN, PhD, Wulf H. Utian, MD, PhD DSc(Med), and Yuan-Mei Liao, RN, PhD This study was conducted to evaluate the psychometric properties of a Chinese-language version of the Utian Quality of Life Scale (UQOL-C). The UQOL-C was shown to be reliable and valid with this sample of women.
448
Age and sex effects on the association between body composition and bone mineral density in healthy Chinese men and women Qun Cheng, MD, Ying Xiao Zhu, BS, Mei Xue Zhang, BSM, Lin Hui Li, BSM, Ping Yan Du, MSM, and Min Han Zhu, MD To understand the distribution of body composition and the relationship of body mass with bone mineral density in China, body composition was measured using dual-energy x-ray absorptiometry in a sample of 3,009 healthy Chinese women and men. Lean mass was the strongest predictor of bone mineral density, whereas fat mass was a complementary factor. In this study, a simple model based on anthropometry for estimating fat mass in white women has been developed. It has been validated and compared with models retrieved from the literature.
471
Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy Maria Pia Rogines-Velo, MD, PhD, Amy E. Heberle, AB, and Hadine Joffe, MD, MSc Depressive symptoms did not emerge during brief treatment with medroxyprogesterone administered sequentially after randomized treatment assignment to estrogen therapy. These findings were consistent for both depressed and nondepressed women, suggesting that even among women who are currently experiencing depression, brief treatment with medroxyprogesterone is unlikely to disrupt mood.
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